Sign in
CompletedPhase 2

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
148 people enrolled
Started
11 Nov 2020
Ended
31 Aug 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sleep Fragmentation
  • Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
  • Sleep Continuity Disruption
  • Undisturbed Sleep
Record updated
24 September 2025

Who can take part

Age
18 years to 48 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Healthy, 18-48 year olds meeting criteria for Normal Sleep
  • Sleep phase within 21:00 and 08:00
  • Total sleep time >6.5 and ≤8.5 hours/night; sleep efficiency ≥85%
  • Non-smokers/nicotine users
  • Low caffeine users (≤ 2 cups, q.d.)
  • Life-time history of exposure to opioids, appropriately prescribed for pain

Who cannot take part

  • Positive toxicology screen for opioids or recreational drugs
  • Had exposure to ionizing radiation that in combination with the study's estimated radiation exposure would result in a cumulative exposure, exceeding recommended limits
  • Lifetime history of chronic pain
  • Meet clinical criteria for a sleep disorder
  • Significant central nervous system disease (e.g., lupus, multiple sclerosis)
  • Cognitive impairment, brain injury or history of closed head injury with loss of consciousness over 3 mins
  • Other significant medical or psychiatric morbidity within 6 months or lifetime history of bipolar disorder, psychotic disorder, seizure disorder
  • Any contraindicated medical condition
  • Lifetime history of alcohol or substance used disorder
  • Clinically significant abnormal complete blood count, hepatic, renal or metabolic panel
  • BMI >35
  • Acute pain
  • Use in the last three months of the following: antidepressants, neuroleptics, sedative hypnotics, isoniazid, glucocorticoids, psychostimulants, opioids
  • Pregnant or lactating women
  • Significant preadmission psychological distress
  • Embedded metal objects or fragments or electronic devices in the head or body that would present a risk during MRI
  • Unable to tolerate the scanning environment/ claustrophobia

Where in United States

  • Johns Hopkins School of MedicineBaltimore, United States

About the trial

What the trial wants to find out

The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) evaluate whether experimental SCD and/or SF alter resting or pain-evoked receptor binding potential in brain regions associated with pain inhibition; 2) examine whether SCD and/or SF alters the analgesic response and abuse liability profile of a study medication; and 3) determine whether receptor binding potentials in brain regions of interest are associated with study medication analgesia and abuse liability. The investigators will also evaluate the extent to which associations differ by sleep condition or sex.

The 3 groups in the trial

  • Sleep Continuity DisruptionTreatment being tested

    The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.

    Treatment: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) and Sleep Continuity Disruption

  • Sleep FragmentationTreatment being tested

    The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.

    Treatment: Sleep Fragmentation and Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)

  • Undisturbed SleepExisting treatment, for comparison

    An 8-hour period of undisturbed sleep is permitted on each night.

    Treatment: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) and Undisturbed Sleep

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Experimental Sleep Disruption and Fragmentation on Study Drug Receptor Function, Receptor Agonist Analgesia, and Abuse Liability
Record updated
24 September 2025